An Interpretable Four-Gene Cell-Cycle Signature Links Malignant Progression to Adverse Survival in Adult Primary Diffuse Glioma: A CGGA Transcriptome Study
Genes · 21.07.2026 · 17 (7) · 833
DOI: 10.3390/genes17070833 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 21.07.2026. Verfasst von Hongkai Jia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Peking University Institute of Nephrology, Peking University First Hospital & Key Laboratory of Renal Disease, Ministry of Health of …. Hauptthemen laut MEDLINE: Glioma, Transcriptome, Brain Neoplasms, Cell Cycle Proteins. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Adult diffuse gliomas are biologically heterogeneous and clinically lethal. We evaluated whether a compact transcriptomic program could summarize malignant progression and adverse survival.
Methods
We analyzed adult primary WHO grades II–IV gliomas from the CGGA mRNAseq_693 cohort and used CGGA mRNAseq_325 as an independent validation cohort. CDK1, CCNB2, CDCA3, and PTTG1 were prioritized through a transparent, literature-informed mitotic-gene framework. Four classifiers were evaluated by five-fold cross-validation repeated 20 times, with all preprocessing restricted to each training fold. A training-defined four-gene score was assessed by Kaplan–Meier and Cox models.
Results
The primary cohort contained 415 tumors, including 396 with evaluable survival. We identified 773 differentially expressed genes between WHO grade IV and WHO grades II/III tumors, and all four candidate genes increased monotonically with grade. In repeated cross-validation, the SVM achieved the highest mean AUROC of 0.793 ± 0.048 (95% CI 0.784–0.802), with average precision of 0.701 ± 0.063. In the independent CGGA mRNAseq_325 cohort (n = 226), logistic regression achieved an AUROC of 0.792. The four-gene score and a broader four-marker proliferation index showed similar discrimination, supporting the interpretation of the signature as a compact proliferation-axis proxy. The training-set median cut-off was −0.153. The score remained associated with shorter survival after adjustment for age, grade, and IDH status in the primary cohort (n = 359; HR = 1.28, 95% CI 1.10–1.49; p = 0.002) and in the independent cohort (n = 217; HR = 1.58, 95% CI 1.25–2.00; p < 0.001).
Conclusions
The four-gene score captures grade-associated proliferative biology and reproducible survival risk across two CGGA cohorts. It is a research biomarker rather than a standalone diagnostic or clinical decision tool.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renal Division, Peking University Institute of Nephrology, Peking University First Hospital & Key Laboratory of Renal Disease, Ministry of Health of China & Key Laboratory of Chronic Kidney Disease Prevention and Treatm…
- College of Bioengineering, Beijing Polytechnic University, Beijing 100176, China.
- Department of Ultrasound Medicine, People's Hospital of Yubei District, Chongqing 401120, China.
Zitieren
APA
Jia, H., Pu, N., & Tian, C. (2026). An Interpretable Four-Gene Cell-Cycle Signature Links Malignant Progression to Adverse Survival in Adult Primary Diffuse Glioma: A CGGA Transcriptome Study. Genes, 17(7), 833. https://doi.org/10.3390/genes17070833
Vancouver
Jia H, Pu N, Tian C. An Interpretable Four-Gene Cell-Cycle Signature Links Malignant Progression to Adverse Survival in Adult Primary Diffuse Glioma: A CGGA Transcriptome Study. Genes. 2026;17(7):833. doi:10.3390/genes17070833
BibTeX
@article{Jia2026,
author = {Jia, Hongkai and Pu, Nan and Tian, Chunyan},
title = {An Interpretable Four-Gene Cell-Cycle Signature Links Malignant Progression to Adverse Survival in Adult Primary Diffuse Glioma: A CGGA Transcriptome Study},
journal = {Genes},
year = {2026},
volume = {17},
number = {7},
pages = {833},
doi = {10.3390/genes17070833}
}
EUVIMED